Testgene - Kit for determination of the status of mutations in the BRCA1 and BRCA2 genes by the NGS method has been registered

Kit for determination of the status of mutations in the BRCA1 and BRCA2 genes by the NGS method has been registered

The TestGene company has registered the kit for determination of the status of mutations in the BRCA1 and BRCA2 genes using the new generation sequencing (NGS) method. The kit makes it possible to detect inherited and somatic mutations responsible for the development of tumors in the human body. The uniqueness of the kit lies in its ease of use. It evenly covers the target genes and analyzes more samples at one time.

The test is carried out by massive parallel sequencing in a sample of human genomic DNA.

"Next generation sequencing is being introduced into routine laboratory practice more and more, since it makes it possible to detect all possible mutations in the tested genes within one analysis unlike PCR. The kit developed by us is designed to detect both inherited and de novo mutations responsible for the development of tumors of the breast, prostate, cervix and pancreas," says Denis Viktorov, Candidate of Biological Sciences, Director of Science at TestGene.

"The widespread use of NGS-based test systems is hampered by the high complexity of the laboratory stage and the need for subsequent bioinformatic processing of the data of sequencing. We tried to solve both problems with our product. We have simplified the procedure for conducting the test to the level of a standard PCR. The reports are prepared using the bioinformation platform that performs all stages of the analysis automatically," added Alexey Nikitin, Head of R&D at TestGene, Candidate of Biological Sciences.

All news